Word from the chairs
“TBVAC-HORIZON provides a unique environment of multidisciplinary research within a Consortium of leading European institutions in the area of academic, clinical and commercial tuberculosis R&D. Its research spans basic and translational science with an interdisciplinary and integrated approach, including clinical studies. This work will advance our understanding of protective immunity, particularly at the site of infection, the lung, consequently facilitating the development of novel TB vaccine candidates. TBVAC-HORIZON will thus innovate and diversify the existing TB vaccine pipeline. As with previous TBVI-led consortia, partners work together to deliver excellent scientific results and outcomes that will secure Europe’s leading role in the development of more effective TB vaccines.”
Prof. Helen McShane, TBVAC-HORIZON’s PI Translational Research
Prof. Steffen Stenger, TBVAC-HORIZON’s PI Basic Research
photo taken by the Oxford Mail
